Long-Term Phase 3 Study Shows Esketamine Nasal Spray Plus an Oral Antidepressant Delayed Time to Relapse in Patients with Treatment-Resistant Depression

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news